Clonixin: a clinical evaluation of a new oral analgesic.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000814:Aniline Compounds / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D002110:Caffeine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D011431:Dextropropoxyphene / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000627:therapeutic use; D009539:Nicotinic Acids / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy*; D010615:Phenacetin / Q000627:therapeutic use; D010919:Placebos; D049590:Postpartum Period; D011247:Pregnancy
D000700:Analgesics; D000814:Aniline Compounds; D000893:Anti-Inflammatory Agents; D009539:Nicotinic Acids; D010919:Placebos; D002110:Caffeine; D009020:Morphine; D010615:Phenacetin; D001241:Aspirin; D011431:Dextropropoxyphene